DVX-201

N/A

Report date: 2023/09/25 09:29:26

Base Information

Drug NameDVX-201

Drug Alias NameDVX-201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDeverra Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCoeptis Therapeutics Holdings Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Myelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A